Literature DB >> 10644842

Insertion sites for recombinant vaccinia virus construction: effects on expression of a foreign protein.

B E Coupar1, P G Oke, M E Andrew.   

Abstract

The expression of antigens or other molecules from recombinant vaccinia viruses requires the insertion of coding sequence at specific sites in the viral genome. Here we investigate the influence of two different sites on the level of protein expressed during a viral infection. The level of immune response in mice to vaccinia virus-expressed murine interleukin 2 (IL-2) or IL-4 varied depending on whether the coding sequence was inserted into the vaccinia virus thymidine kinase (tk) gene or into the HindIII F fragment of the viral genome where herpes simplex virus (HSV) tk was used as a selectable marker. In each case the intensity of the response was greater when the relevant gene was expressed from the HindIII F insertion site. In order to quantify these differences a series of recombinant viruses expressing luciferase was constructed. Luciferase activity from coding sequence inserted into the HindIII F fragment was significantly higher than that from the tk gene insertion, provided HSV tk(+) constructs were compared. Insertion of a marker gene (HSV tk) into the HindIII F site with disruption of the F7L open reading frame led to a reduced level of luciferase expressed from the tk insert, despite more than 45 kb of intervening sequence. In mice, luciferase expression was higher from the HindIII F inserted gene than from the tk insert in both lungs and ovaries.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644842     DOI: 10.1099/0022-1317-81-2-431

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Attenuation of vaccinia virus by the expression of human Flt3 ligand.

Authors:  Kamila Zurkova; Petr Hainz; Jitka Krystofova; Luda Kutinova; Miloslav Sanda; Sarka Nemeckova
Journal:  Virol J       Date:  2010-05-26       Impact factor: 4.099

2.  Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy.

Authors:  Nanhai Chen; Clifford J Bellone; Jill Schriewer; Gelita Owens; Torgny Fredrickson; Scott Parker; R Mark L Buller
Journal:  Virology       Date:  2010-11-10       Impact factor: 3.513

3.  Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing.

Authors:  Tomoyoshi Inoue; Thomas Byrne; Mitsuko Inoue; Madeline E Tait; Patrick Wall; Annabel Wang; Michael R Dermyer; Hanane Laklai; Joseph J Binder; Clare Lees; Robert Hollingsworth; Liliana Maruri-Avidal; David H Kirn; Donald M McDonald
Journal:  Mol Cancer Ther       Date:  2021-05-27       Impact factor: 6.261

4.  Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).

Authors:  Matthew G Cottingham; Rikke F Andersen; Alexandra J Spencer; Saroj Saurya; Julie Furze; Adrian V S Hill; Sarah C Gilbert
Journal:  PLoS One       Date:  2008-02-20       Impact factor: 3.240

5.  Drug-Encoded Biomarkers for Monitoring Biological Therapies.

Authors:  Desislava Tsoneva; Jochen Stritzker; Kristina Bedenk; Qian Zhang; Alexa Frentzen; Joseph Cappello; Utz Fischer; Aladar A Szalay
Journal:  PLoS One       Date:  2015-09-08       Impact factor: 3.240

6.  Bioluminescent imaging of vaccinia virus infection in immunocompetent and immunodeficient rats as a model for human smallpox.

Authors:  Qiang Liu; Changfa Fan; Shuya Zhou; Yanan Guo; Qin Zuo; Jian Ma; Susu Liu; Xi Wu; Zexu Peng; Tao Fan; Chaoshe Guo; Yuelei Shen; Weijin Huang; Baowen Li; Zhengming He; Youchun Wang
Journal:  Sci Rep       Date:  2015-08-03       Impact factor: 4.379

Review 7.  Use of Reporter Genes in the Generation of Vaccinia Virus-Derived Vectors.

Authors:  Sally Al Ali; Sara Baldanta; Mercedes Fernández-Escobar; Susana Guerra
Journal:  Viruses       Date:  2016-05-21       Impact factor: 5.048

8.  Modified Vaccinia Virus Ankara Can Induce Optimal CD8+ T Cell Responses to Directly Primed Antigens Depending on Vaccine Design.

Authors:  Yik Chun Wong; Sarah Croft; Stewart A Smith; Leon C W Lin; Tania Cukalac; Nicole L La Gruta; Ingo Drexler; David C Tscharke
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.